Nordson Corporation (NASDAQ: NDSN), which designs and manufactures dispensing equipment for consumer and industrial adhesives and sealants, has announced financial results for the fourth quarter of fiscal 2025.
- Fourth-quarter sales increased 1% year-over-year to $752 million; Advanced Technology Solutions sales were down 4%
- Industrial Precision Solutions sales decreased 2% from last year, while Medical and Fluid Solutions sales rose 10%
- Net income was $152 million or $2.69 per share in Q4, compared $122 million or $2.12 per share last year
- Adjusted net income rose to $171 million in the fourth quarter from $160 million in the prior-year period
- On a per-share basis, adjusted earnings moved up to $3.03 from $2.78 in the corresponding quarter last year
- BITDA was $256 million, or 34% of sales, in Q4, an increase of 6% from $241 million, or 32% of sales, reported in the prior-year quarter
- For the first quarter, the company expects sales to be in the range of $630 million to $670 million, and adjusted earnings per share in the range of $2.25 to $2.45
- The management expects sales to be in the range of $2.83 billion to $2.95 billion in fiscal 2026.
- Full-year adjusted earnings are forecasted to be in the range of $10.80 per share to $11.50 per share
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
After a rollercoaster year, is Tesla (TSLA) stock a good bet?
In recent years, Tesla's (NASDAQ: TSLA) stock has often swung between record highs and sharp corrections, reflecting shifts in investor sentiment, broader economic conditions, and changes in its financial performance.
Dollar Tree (DLTR), Dollar General (DG): Discount stores remain key gainers in a value-conscious landscape
Discount retailers Dollar Tree, Inc. (NASDAQ: DLTR) and Dollar General Corporation (NYSE: DG) have seen their stocks gain more than 30% in the past three months. The dollar stores continue
Everything you need to know about Aktis Oncology’s upcoming IPO
IPO activity in 2025 showed a marked rebound, led by the technology and healthcare sectors, after last year's sluggish performance. Aktis Oncology, which develops radiopharmaceuticals for solid tumors, is the
